September 1, 2020
The Board of Trustees of the Georgia Research Alliance has named Susan Shows as the organization’s fourth president, effective September 1, 2020.
Since 2008, Shows has served as GRA’s senior vice president, managing the Alliance’s $649 million portfolio of investment in talent and technology at Georgia’s leading research universities. In this role, she has been instrumental in helping the universities recruit world-class scientists to Georgia as GRA Eminent Scholars and making strategic investments in lab infrastructure to help the Scholars expand their work.
Shows also manages much of GRA’s financial analytics, guiding the organization’s long-term strategic planning and providing transparency to the Alliance’s partners in state government.
June 5, 2020
Board Chair David Ratcliffe writes fellow Trustees on the 30th anniversary of GRA
June 6, 2020 marks the 30th anniversary of the Georgia Research Alliance. For the rest of the year, GRA will celebrate with acknowledgments and appreciations of those who helped build and develop the organization.
GRA Board Chair David Ratcliffe kicks us off with the following letter, sent to fellow Trustees on the GRA Board on Friday afternoon, June 5:
June 5, 2020
Anniversaries sometimes have a way of sneaking up on you. An important one arrives tomorrow: The 30th year of the Georgia Research Alliance.
What began as a novel idea in the late 1980s became a unique organization in 1990 – a true alliance of government, private industry and academia, working together to grow Georgia's economy by expanding university research and entrepreneurship.
You probably remember when you first learned about GRA.
May 26, 2020
A quick rundown of impressive activities in our state's university labs and startups
In ways imaginative and pragmatic, Georgia’s university scientists and startup companies have gotten into the fight against COVID-19.
Here are some examples of how GRA-backed researchers and entrepreneurs in our state are applying expertise and ingenuity against the coronavirus.An experimental drug developed at Emory University to treat the COVID-19 disease has begun Phase 2 clinical testing in humans. The treatment is being licensed by Ridgeback Biotherapeutics through DRIVE, LLC, an Emory nonprofit working to bring the drug to market.